• Molecular NameMilrinone
  • SynonymMilrinone Lactate
  • Weight211.224
  • Drugbank_IDDB00235
  • ACS_NO78415-72-2
  • Show 2D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)1.0
  • pka5.2
  • LogD (pH=7, predicted)0.98
  • Solubility (experiment)Slightly soluble
  • LogS (predicted, ACD/Labs)(ph=7)-1.65
  • LogSw (predicted, AB/LogsW2.0)6.22
  • Sw (mg/ml) (predicted, ACD/Labs)3.54
  • No.of HBond Donors1
  • No.of HBond Acceptors4
  • No.of Rotatable Bonds2
  • TPSA65.78
  • StatusFDA approved
  • AdministrationIV only
  • PharmacologyA phosphodiesterase III inhibitor. It potentiates the effect of cyclic adenosine monophosphate (cAMP).
  • Absorption_value100.0
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability86.0
  • Protein binding75.0
  • Volume of distribution (VD)0.3 to 0.42 L/kg (after doses of 12.5 to 75 μg/kg administered to congestive heart failure patients intravenously) and 0.32 L/kg (after doses of 10 to 125 μg/kg administered to healthy individuals).
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmHepatic (12%)
  • Half life2.3 h
  • ExcretionUrine (85% as unchanged drug) within 24 hours
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityN/A
  • LD50 (rat)LD50=0.3 mg/L
  • LD50 (mouse)N/A